{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:17:39Z","timestamp":1780582659915,"version":"3.54.1"},"reference-count":33,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>\n                      Colistin became the critical treatment option for multidrug-resistant Gram-negative bacteria (GNB); however, resistance to colistin is increasingly being reported among clinical isolates. New therapy strategies should be considered nowadays. The aim of this study was to investigate the\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      activity of a novel \u03b2-lactam\/\u03b2-lactamases inhibitor ceftazidime-avibactam (CZA) alone and in combination with amikacin against colistin-resistant Gram-negative pathogens.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among all the colistin-resistant GNB strains, 30.4% (21\/69) were resistant to CZA, which was similar to the resistance rate of 25.4% (35\/138) in colistin-susceptible strains (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&gt;\u20090.05), displaying a relatively lower resistance rate compared with other antimicrobial agents (except amikacin). A majority of CZA-resistant GNB isolates (33\/56) produced NDM carbapenemase. The fractional inhibitory concentration index method revealed synergistic (47.6%, 10\/21) or additive (52.4%, 11\/21) effects of CZA in combination with amikacin against colistin- and CZA-resistant GNB isolates, wherein the synergistic activity was found against all tested\n                      <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                      isolates (four) and\n                      <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                      isolates (two). The time-killing curve assay verified the synergistic activity of CZA and amikacin in\n                      <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                      (FK2778)\n                      <jats:italic toggle=\"yes\">and P. aeruginosa<\/jats:italic>\n                      (TL2294). The susceptible breakpoint index values showed that CZA in combination with amikacin reduced the MIC to less than the susceptibility breakpoint among 71.4% (15\/21) of all tested strains.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      CZA may be a new alternative for colistin-resistant Gram-negative infections and pending clinical studies combining CZA with amikacin should be considered against these pathogens, particularly for\n                      <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">P. aeruginosa.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/mdr.2019.0463","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T17:53:24Z","timestamp":1595958804000},"page":"401-409","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["<i>In Vitro<\/i>\n                    Activity of Ceftazidime-Avibactam Alone and in Combination with Amikacin Against Colistin-Resistant Gram-Negative Pathogens"],"prefix":"10.1177","volume":"27","author":[{"given":"Tao","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihang","family":"Yu","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Zeng","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunquan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Cao","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tieli","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2017.1308251"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2016.1204911"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066615619895"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00077-17"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.10.011"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/429323"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","unstructured":"Perez F. El Chakhtoura N.G Yasmin M. and Bonomo R.A.. 2019. Polymyxins: to combine or not to combine? Antibiotics (Basel). 8:38.","DOI":"10.3390\/antibiotics8020038"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00271-19"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.01808"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1179\/1973947813Y.0000000136"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky134"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070934"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0725-1"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix783"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.04.003"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2017.12.010"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx483"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.01.008"},{"key":"e_1_3_4_20_2","first-page":"154","article-title":"[In-vitro activity of ceftolozane-tazobactam in combination with various antibiotics against multidrug-resistant Acinetobacter baumannii isolated from intensive care patients]","volume":"54","author":"Aky\u00fcz S.","year":"2020","unstructured":"Aky\u00fcz S., , Parlak M., , and G\u00fcd\u00fcc\u00fco\u011flu H.. 2020. [In-vitro activity of ceftolozane-tazobactam in combination with various antibiotics against multidrug-resistant Acinetobacter baumannii isolated from intensive care patients]. Mikrobiyol. Bul. 54:154\u2013162.","journal-title":"Mikrobiyol. Bul"},{"key":"e_1_3_4_21_2","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing 28th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_4_22_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. 2017. Breakpoint tables for interpretation of MICs and zone diameters Version 7.1. Available at www.eucast.org."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.28"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2018.0234"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp384"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz010"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(06)70580-1"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.06.023"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00215"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01224-17"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","unstructured":"Wang Y. Wang J. Wang R. and Cai Y.. 2019. Resistance to Ceftazidime-Avibactam and Underlying Mechanisms. J. Glob. Antimicrob. Resist. [Epub ahead of print]; DOI:10.1016\/j.jgar.2019.12.009.","DOI":"10.1016\/j.jgar.2019.12.009"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy659"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.11.24"},{"key":"e_1_3_4_34_2","first-page":"953","volume":"75","author":"Gofman N.","year":"2018","unstructured":"Gofman N., , To K., , Whitman M., , and Garcia-Morales E.. 2018. Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin. Am. J. Health Syst. Pharm. 75:953\u2013957.","journal-title":"Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin. Am. J. Health Syst. Pharm"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2019.0463","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0463","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:37:09Z","timestamp":1777667829000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2019.0463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"alternative-id":["10.1089\/mdr.2019.0463"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2019.0463","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}